Adaptive Biotechnologies vs Iovance Biotherapeutics
ADPT and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADPT and IOVA compare
Adaptive Biotechnologies is the larger company, worth 1.3 times as much as Iovance Biotherapeutics ($4.6B against $3.5B).
Iovance Biotherapeutics grew revenue faster over the last twelve months (51.3% versus 17.9% for Adaptive Biotechnologies).
Adaptive Biotechnologies keeps more of each dollar of sales as profit, with a net margin of −23.7% compared with −58.2% at Iovance Biotherapeutics.
Adaptive Biotechnologies scores higher on the StockData Score (12 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADPT | IOVA |
|---|---|---|
| Size and price | ||
| Market cap | $4.6B | $3.5B |
| Share price | $29.04 | $7.76 |
| Change, 1 year | 100% | 206% |
| Change, 5 years | 6.2% | −58.8% |
| Beta (5Y) | 1.79 | 1.29 |
| Employees | 624 | 975 |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 2 |
| Performance score | 3 (better) | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.6× | 9.3× (better) |
| P/B | 26.3× | 4.3× (better) |
| FCF yield | −0.19% (better) | −6.1% |
| Fair value | $6.88 | $4.47 |
| Margin of safety | −322% | −73.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 17.9% | 51.3% (better) |
| Revenue growth, 5Y average | 23.0% | – |
| Profitability | ||
| Gross margin | 74.2% (better) | 53.2% |
| Operating margin | −16.2% (better) | −60.8% |
| Net margin | −23.7% (better) | −58.2% |
| FCF margin | −3.0% (better) | −57.0% |
| Return on equity | −37.1% | −29.1% (better) |
| Return on invested capital | −9982% | −43.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −5.3× | – |
| Current ratio | 3.97 | 5.20 (better) |
| Altman Z-score | 3.38 | 7.83 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −8.3% |
| Shareholder yield | 0.00% (better) | −8.3% |
| Ownership | ||
| Held by institutions | 97.6% | 63.3% |
| Held by insiders | 22.7% | 0.38% |
| Insider net buying, 12 months | −$117M | – |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 14.4% |
Go deeper
- ADPT stock overview
- ADPT income statement
- ADPT valuation and score
- IOVA stock overview
- IOVA income statement
- IOVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.